昨日三大指数集体收涨，沪指高开高走，再创十年新高。量能持续放大，沪深两市成交额2.81万亿，较 上一个交易日放量2602亿。盘面上，市场热点轮番活跃，全市场超4100只个股上涨，其中有143只个股 涨停，连续两日超百股涨停。从板块来看，商业航天概念持续爆发，脑机接口概念延续强势，化工板块 走高；截至收盘，沪指涨1.5%，深成指涨1.4%，创业板指涨0.75%。 商务部加强两用物项对日本出口管制，如果日本厂商的生产因出口管制而受到冲击，直接利好中国氧化 锆粉体厂商加速出海扩大市场份额，同时日本氧化锆厂商的客户也将受到影响，利好对应的中国同行获 取市场份额。 开源证券：脑机接口产业落地有望提速 马斯克在社交媒体上宣布脑机接口公司Neuralink今年将开启"大规模量产"，并转向更精简、全自动化的 外科手术流程。与此同时，脑机接口作为国内十五五规划明确布局的未来产业，政策也在持续加码，中 国的脑机接口公司正在加速临床，并呈现多种技术路线并行的格局。一场集体"插脑"竞赛进入冲刺阶 段。全球脑机接口领域竞争激烈，随着政策、技术与临床进展、想象力三重动力共振，A股市场脑机接 口概念板块火热，行情持续发酵。多重政策强力支持 ...

Group 1: Market Overview - The three major indices collectively rose, with the Shanghai Composite Index reaching a ten-year high, closing up 1.5% [1] - Trading volume increased significantly, with a total turnover of 2.81 trillion yuan, up 260.2 billion yuan from the previous trading day [1] - Over 4,100 stocks in the market rose, with 143 stocks hitting the daily limit up, marking the second consecutive day of over 100 limit-up stocks [1] Group 2: Sector Insights - The commercial aerospace sector continues to thrive, while the brain-computer interface (BCI) sector maintains strong momentum, and the chemical sector is also performing well [1] - Citic Securities views the Ministry of Commerce's strengthened export controls on dual-use items to Japan as a positive for Chinese zirconium oxide manufacturers, who may gain market share as Japanese firms face production disruptions [2] - Open Source Securities anticipates accelerated development in the BCI industry, driven by Elon Musk's Neuralink announcing plans for large-scale production and streamlined surgical processes [3] Group 3: Investment Opportunities - Citic Jiantou believes the humanoid robot sector is in a bottom rebound phase, with expectations for upward revisions pending new catalysts or progress in mass production [1] - The BCI sector is experiencing a competitive surge, supported by policies, technological advancements, and clinical progress, creating significant investment opportunities in the A-share market [3]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a surge in investor interest, driven by technological breakthroughs and product approvals in China, alongside Elon Musk's announcement of mass production of BCI products by Neuralink within the year [1][3]. Industry Developments - The BCI industry is in a high-growth phase, supported by technological advancements, policy backing, and collaborative expectations within the robotics ecosystem, with projections indicating the global BCI medical application market could reach $40 billion by 2030 and $145 billion by 2040 [3]. - Recent breakthroughs include the first clinical trial of a fully implanted, wireless BCI product by Brain Tiger Technology, which offers hope for patients with severe paralysis [3][4]. Company Responses - Multiple A-share listed companies have responded to the heightened interest in the BCI sector, with announcements detailing their business progress in this area [1][6]. - Xiangyu Medical reported a 44% cumulative increase in stock price, emphasizing its focus on non-invasive BCI technology, while acknowledging that its products have not yet achieved significant sales [6][9]. - Weisi Medical also clarified that its BCI products are in the early market cultivation stage and primarily focus on non-invasive technologies, with limited revenue contribution [9][10]. Strategic Collaborations - Companies are actively forming partnerships to enhance their BCI capabilities. Baiyang Pharmaceutical announced a collaboration with Capital Medical University to establish a joint laboratory focused on neuroscience and BCI research [11]. - Kefu Medical disclosed investments in non-invasive BCI robotics and implantable BCI companies, aiming for business synergy [11]. Technological Innovations - Companies like Sanbo Brain Science are making progress with their BCI technologies, including the development of a flexible microelectrode system for brain signal acquisition [12]. - In the semiconductor sector, companies are producing specialized chips for high-precision measurement of biological signals, which are essential for BCI applications [13]. Market Recognition - Domestic BCI products are gaining international recognition, with Shenzhou Rehabilitation's spinal interface product receiving breakthrough therapy designation from the FDA, marking a significant achievement for Chinese companies in the BCI field [4].

Core Viewpoint - The brain-computer interface (BCI) concept continues to gain traction, with multiple listed companies responding positively to the trend, leading to significant stock price increases in the sector [1]. Company Responses - On January 6, several companies, including Weisi Medical, Sanbo Brain Science, Aipeng Medical, and others, saw their stocks hit the daily limit, with many achieving consecutive gains [3]. - Weisi Medical reported a 20.01% increase in stock price, indicating a strong market response to its developments in the neuro-rehabilitation field, expanding from single-device solutions to comprehensive "diagnosis-treatment-rehabilitation" offerings [4][5]. - Sanbo Brain Science highlighted the promising applications of BCI technology in clinical diagnosis and neuro-rehabilitation, also achieving a 20.01% stock price increase [7]. - Xiangyu Medical announced the establishment of a BCI laboratory and aims to develop a product system covering four major categories, also achieving a two-day stock increase [8]. - Aipeng Medical's stock rose by 20%, emphasizing the role of BCI as a bridge between the brain and external devices [9][10]. - Entropy Technology and Meihua Medical also reported significant stock increases, with the former focusing on BCI and vehicle-road collaboration technologies [11][12]. Industry Developments - Companies are actively engaging in the BCI sector, with Xiangyu Medical entering over 500 medical institutions and aiming for over a thousand top-tier hospitals nationwide, indicating a robust commercialization strategy [15]. - Mcland anticipates obtaining its first BCI medical device registration certificate by Q1 2026, which could accelerate the application of BCI technology in existing product lines [15]. - Chengdu Huayi and Yingjixin are focusing on the foundational hardware for BCI, with Chengdu Huayi developing high-precision ADCs and low-power FPGAs for signal processing [15][16]. - The integration of BCI with embodied intelligence is gaining attention, with companies exploring applications in smart healthcare and rehabilitation [17]. - Blue Si Technology announced its strategic investment in Qiang Brain Technology, which recently secured approximately 2 billion yuan in funding, marking it as the second-largest financing in the BCI field after Neuralink [18]. Market Outlook - The global BCI market is projected to reach approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, driven by technological advancements and increased capital investment [20]. - The transition of BCI from clinical validation to commercial scalability is expected to unlock significant market opportunities in healthcare and consumer sectors [20].

Core Viewpoint - The company Aihuilong has signed a strategic cooperation framework agreement with Brain Machine Star Chain, focusing on market expansion and sales of Brain Machine Star Chain's existing and in-development products, with a revenue-sharing model based on future agreements [3]. Group 1: Company Overview - Aihuilong is a provider of in vitro diagnostic products, primarily engaged in the research, production, and sales of in vitro diagnostic instruments and related reagents using chemiluminescence immunoassay technology [3]. - Brain Machine Star Chain, established in September 2025 with a registered capital of 5 million yuan, focuses on comprehensive diagnosis, treatment, and rehabilitation of brain diseases, integrating research, development, production, sales, and technical support [3]. Group 2: Strategic Cooperation Details - The cooperation aims to leverage Aihuilong's strong sales channels in emergency, brain disease diagnosis, and pediatrics to empower Brain Machine Star Chain's market expansion [3]. - The agreement is a framework and does not specify financial amounts, with no significant impact on Aihuilong's operating performance expected for the current year [3]. Group 3: Market and Financial Context - Aihuilong's stock price increased by 6.52% on January 6, with trading volume rising by 299% compared to the previous day, prompting inquiries from the Shanghai Stock Exchange regarding insider trading [5]. - The Shanghai Stock Exchange has requested Aihuilong to disclose details about Brain Machine Star Chain's resources for further research or commercialization, as well as the feasibility and timeline of their collaborative efforts [4]. Group 4: Product Development Status - Brain Machine Star Chain is currently developing non-invasive technology products, including brainwave collection and analysis devices, sleep aids, and vagus nerve stimulators, with some products still in early research or preclinical stages [9]. - The company has no invasive technology layout, distinguishing its approach from that of Neuralink, founded by Elon Musk [9].

Group 1 - The core viewpoint of the news is that the brain-computer interface (BCI) sector is experiencing significant growth, highlighted by the recent 2 billion yuan financing of Qiangnao Technology, marking it as the second-largest financing in the field after Neuralink [2][3] - The BCI sector has become the hottest investment track in the A-share market since the beginning of 2026, with multiple stocks like Innovation Medical, Aipeng Medical, and Xiangyu Medical achieving consecutive trading limits [2] - Qiangnao Technology is recognized as one of the "Hangzhou Six Little Dragons," focusing on the research and development of BCI products, and has received FDA and CE certifications, making it one of the largest investors in BCI R&D globally [3][4] Group 2 - Qiangnao Technology was founded in February 2015 and has launched several products, including smart bionic limbs and brain-machine intelligent sleep devices [3] - The company has a strong investor lineup, including IDG, Huaden International, and several strategic investors, indicating robust market confidence [3] - The BCI industry is currently in a high-growth phase driven by policy support and technological breakthroughs, with expectations for Neuralink to begin large-scale production in 2026 [4] Group 3 - Several BCI stocks, including Sanbo Brain Science, Maillande, and Xiangyu Medical, have issued announcements regarding abnormal stock trading fluctuations, warning investors of potential risks [5] - Sanbo Brain Science reported a significant stock price increase but clarified that it does not engage in BCI product development, indicating minimal impact on its financial performance [7] - Xiangyu Medical highlighted its focus on non-invasive BCI technology and aims to commercialize its products in over a thousand top-tier hospitals by 2026 [11]

Core Viewpoint - BrainCo, a prominent brain-computer interface (BCI) company in Hangzhou, has gained global attention due to its non-invasive technology and mass production capabilities, positioning itself as a competitor to Neuralink [1][2]. Group 1: Company Overview - Founded in 2015 by Harvard alumnus Han Bicheng, BrainCo is recognized as China's first BCI unicorn and has made significant advancements in non-invasive technology [1][2]. - The company has received major international certifications, including FDA and CE, and ranks among the top in global BCI research and development investments [2]. - BrainCo's flagship product, the BrainRobotics smart bionic hand, has been featured on the cover of TIME magazine's Best Inventions of the Year [2]. Group 2: Technological Innovations - BrainCo's core technology, the super sensor, captures weak brain signals without invasive procedures, enabling applications in rehabilitation for disabled individuals and treatment for conditions like autism and Alzheimer's [4]. - The company has successfully launched products such as the smart bionic hand and bionic leg, which allow users to perform complex movements, showcasing the practical impact of BCI technology [4]. Group 3: Market Position and Financing - BrainCo recently completed a financing round of approximately 2 billion RMB, making it the second-largest financing in the global BCI sector after Neuralink [5]. - The investment consortium includes renowned firms like IDG and strategic partners such as Lens Technology, indicating strong market confidence in BrainCo's potential [5]. - The company is preparing for an IPO, with plans to list in Hong Kong or on the STAR Market, reflecting its growth trajectory and market ambitions [5]. Group 4: Future Prospects - Han Bicheng envisions BCI technology transforming everyday life, with plans to assist 1 million disabled individuals and 10 million patients with brain-related conditions over the next 5 to 10 years [7]. - The demand for BCI solutions is significant, given that over 24 million people in China live with physical disabilities, alongside rising cases of brain diseases [7]. - BrainCo's growth is supported by Hangzhou's favorable innovation environment and government funding, which has been crucial for its development [8].

Core Viewpoint - The article highlights the rapid growth and investment activity in the brain-computer interface (BCI) sector, particularly focusing on the recent significant financing of Qiangnao Technology, which has raised approximately 2 billion yuan, marking it as the second-largest financing in the BCI field globally after Neuralink [2][3]. Investment Landscape - The BCI sector has emerged as a hot investment area in the A-share market since the beginning of 2026, with multiple stocks such as Innovation Medical, Aipeng Medical, and Xiangyu Medical experiencing consecutive trading gains [2]. - Qiangnao Technology, part of the "Hangzhou Six Little Dragons," has attracted a strong lineup of investors, including IDG and major tech firms, and has received FDA and CE certifications for its products [3][4]. Company Developments - Qiangnao Technology, founded in 2015, focuses on non-invasive BCI technology and has launched several products, including smart bionic limbs and brain-machine sleep aids [3]. - The company has a history of significant funding rounds, including a $400 million Series A round in 2019 and subsequent rounds totaling $30 million and $20 million in 2025 [4]. Market Dynamics - The BCI industry is currently experiencing a dual boost from policy support and technological breakthroughs, with expectations for Neuralink to begin large-scale production of BCI devices in 2026 [4]. - Companies like Sanbo Brain Science, Meilan De, and Xiangyu Medical have issued announcements regarding stock trading volatility, indicating the heightened interest and speculative nature of the market [5][6]. Product and Technology Focus - Xiangyu Medical is concentrating on non-invasive BCI technology and has made significant investments in R&D, with over 60% of its R&D budget directed towards BCI-related projects [7]. - The company aims to integrate BCI technology with its rehabilitation equipment, targeting to cover over 1,000 top-tier hospitals by 2026 [7].

Core Insights - Elon Musk announced plans for mass production of brain-computer interface (BCI) products within the year, igniting investor enthusiasm in the BCI sector [1] - Recent technological breakthroughs and product approvals in China's BCI industry have bolstered confidence in its growth [1] Market Performance - The BCI sector experienced a surge, with multiple companies hitting their daily price limits, including BeiYikang with a 69% increase over two days [1] - Notable stock performances include: - BeiYikang: +29.98% at 58.44 - WeiSi Medical: +20.01% at 69.70 - Sanbo Brain Science: +20.01% at 84.94 - AiPeng Medical: +20.00% at 39.96 - Xiangyu Medical: +20.00% at 87.12 [2] Technological Advancements - The BCI technology is transitioning from laboratory research to clinical and industrial applications, driven by technological breakthroughs and policy support [3] - McKinsey predicts the global BCI medical application market could reach $40 billion by 2030 and $145 billion by 2040 [3] - Domestic companies like Brain Tiger Technology have achieved significant milestones, including the first clinical trial of a fully implanted, wireless BCI product [3][4] Company Developments - Several A-share listed companies have responded to the heightened interest in BCI, emphasizing their early-stage involvement in the sector [5][10] - Xiangyu Medical reported a 44% cumulative increase in stock price and highlighted its focus on non-invasive BCI technologies [6][9] - WeiSi Medical and Sanbo Brain Science both noted that their BCI products are still in the early stages of market development, with limited revenue contribution [9][10] Collaborative Efforts - Companies are forming partnerships to advance BCI research, such as Baiyang Pharmaceutical's collaboration with Capital Medical University [11] - Kuofu Medical has invested in non-invasive BCI robotics and previously in implantable BCI companies, indicating a strategic approach to market entry [11] Industry Participation - Various sectors, including semiconductors and new materials, are leveraging their technological strengths to capitalize on BCI opportunities [12][13] - Companies like Yiwai Lithium Energy and Lens Technology are collaborating with leading BCI firms to enhance their product offerings [13]

1月6日，亚辉龙(688575)公告，公司近日与深圳脑机星链科技有限公司（简称"脑机星链"）签署了《战 略合作框架协议》，双方共同达成战略合作，通过整合脑机接口技术与临床和市场资源，共同开发脑机 接口相关在研产品及推进后续市场拓展及推广，提升在中枢神经疾病等领域诊疗技术水平。 亚辉龙称，该协议属于框架性协议，预计对公司本年度经营业绩不构成重大影响，对公司未来年度经营 业绩的影响将视后续具体项目推进和实施情况而定。 亚辉龙还称，脑机星链目前在研产品的技术路线为非侵入式技术路径，与马斯克创建的脑机接口公司 Neuralink在技术路线上存在本质区别，目前也尚无侵入式技术布局。 记者注意到，亚辉龙披露相关公告后，上交所火速下发问询函，并要求公司于1月8日之前披露回复。 上交所要求亚辉龙补充披露，脑机星链主要技术路线、主要产品类型、应用领域、产品所处研发或商业 化状态，其自身是否具备推进后续研发或商业化的各类资源；结合公司主营业务，说明双方产品在应用 领域、客户、渠道等方面的协同性，分析合作开展市场推广的可行性； 结合脑机星链产品研发进展，说明双方未来签署后续推广协议的预计时间安排，双方预计开展市场推广 和公司预计取 ...